Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
- MeSH Terms
- Breast Neoplasms, breast tumor, breast cancer, breast neoplasm, Diphosphonates, bisphosphonic acid derivative, bisphosphonate, zoledron, ibandron, pamidron, risedron, alendron, neridron, olpadron, clodron, tiludron, etidron, reclast, zometa, aclasta, boniva, aredia, actonel, fosamax, nerixia, bonefos, loron, skelid, didronel, Bone Density Conservation Agents, Endothelin A Receptor Antagonists, denosumab, calcitonin, dasatinib, rilotumumab, cabozantinib, bone-modifying agent, atrasentan, zibotentan, dasatinib, rilotumumab, AMG102, cabozantinib, Prolia, Xgeva, Fortical, Miacalicin, Evista
- Guideline Contact
- Glenn Fletcher; [email protected]
- Keywords
- breast neoplasms, breast cancer, diphosphonates, bisphosphonate, bone-modifying agent, adjuvant therapy
- Date for Review
- In Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario), we have an annual review process for each guideline after it is completed. Guidelines are reviewed every fall after they are older than 1 year.
- Publication Date
- 2022-07-14
- Date of Last Evidence Search
- 2021-01-28
- Methods Applied
- Evidence-based, Systematic review-based, Externally reviewed, Evidence quality assessmen
- Publication Scope
- Guidelines
- treatment
- Countries of Application
- Canada
- Guideline Publication Status
- Published
- Languages
- English
- Authors
- PEBC (Program in evidenced-based care)
- Publication Year
- 2022